Prospective Study of Immune Function and PD-1 Antibody Therapy Efficacy Predictors on CAEBV and EBV-HLH Patients

NCT05841342 · clinicaltrials.gov ↗

UNKNOWN

Status

128

Enrollment

OTHER

Sponsor class

Conditions

Secondary Hemophagocytic Lymphohistiocytosis
Chronic Active Epstein-Barr Virus Infection

Interventions

OTHER: No intervention

Sponsor

Beijing Friendship Hospital